Global Next Generation Cancer Diagnostics Market to 2027: Featuring Abbott Laboratories, Abbvie, Advanced Cell Diagnostics, Agilent Technologies and Artivion Among Others - ResearchAndMarkets.com

10 May 2023
www.businesswire.com
Diagnostic Reagents
DUBLIN--(BUSINESS WIRE)--The "Next Generation Cancer Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
'Next Generation Cancer Diagnostics: Technologies and Global Markets'
The base year for market data is 2021, with historical data provided for 2020 and 2019 and forecast data provided through 2027. Historical, base year, and forecast data are provided for each market segment of the report.
Companies Mentioned
Commence Bio
Dragerwerk AG & Co. Kgaa
Geron
Merck Kgaa
An increasing number of cancer cases globally is one of the significant factors contributing to industry growth during the forecast period. Technological advancements in diagnostic tests are further expected to fuel industry growth. Moreover, supportive government initiatives and rising awareness are additional factors anticipated to boost growth during the forecast period.
For instance, the Biden-Harris administration has set a goal of decreasing the cancer mortality rate by 50% over the next 25 years and enhancing the knowledge surrounding people living with and surviving tumors.
Cancer is one of the leading causes of death worldwide, and the prevalence of the disease has been escalating at an alarming rate. Therefore, healthcare professionals are focusing on developing effective screening and treatment solutions to check prevalence levels. Early screening increases the success rate of treatment regimens. As a result, healthcare agencies and market players, through various awareness programs, are promoting routine check-ups and screenings. For instance, in March 2022, HHS announced funding of $5 million to improve equity in cancer screening at health centers.
The global oncology burden is projected to reach 28.4 million cases in 2040, a 47% growth from 2020. Thus, a rise in the incidence is anticipated to boost the adoption of cancer diagnostic products.
In April 2022, the Precision Cancer Consortium (PCC) collaborated with pharmaceutical companies by permitting access to comprehensive testing for all cancer patients globally. The PCC drives diverse initiatives to grow patient access to precision diagnostics using wide-ranging genomic testing, including next generation sequencing (NGS). The founding members of PCC include Novartis, Bayer, Roche, and GlaxoSmithKline.
Advanced diagnostics for cancer represent a significant market opportunity for life sciences companies. Many cancer types are on the rise as the aging populations of many countries continue to grow. As a result, there is an increasing demand for noninvasive diagnostic assays that can detect cancers earlier, molecularly subtype tumors to guide therapy decisions and monitor cancer recurrence in treated individuals.
Key Attributes:
Report Attribute
Details
No. of Pages
166
Forecast Period
2022 - 2027
Estimated Market Value (USD) in 2022
$8.7 Billion
Forecasted Market Value (USD) by 2027
$15 Billion
Compound Annual Growth Rate
11.5%
Regions Covered
Global
Report Includes
15 data tables and 80 additional tables
An overview of the global market and technologies for next generation cancer diagnostics
Estimation of the market size and analyses of global market trends, with data from 2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027
Highlights of the current and future market potential and quantification of next generation cancer diagnostics market based on type, application, and region
Description of arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
Analysis of underlying technological, environmental, legal/regulatory, and political trends that may influence the size and nature of the market
Coverage of the key initiatives and programs related to the next generation cancer diagnostics market
Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
Company profiles of major players within the industry, including Abbott Laboratories, Illumina Inc., Becton, Dickinson and Co., and Illumina Inc.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
3.1 Overview
3.2 Next Generation Sequencing in Personalized Medicine
3.3 NGS in Clinical Oncology
3.4 Large-Scale Initiatives and Consortia
3.5 Liquid Biopsy Technologies
3.6 Liquid Biopsy as a Market-Driving Force
3.7 Industry
3.8 Diagnostics Overview
3.9 Arrays and Microfluidics (Loac) Technologies
3.10 Multiplex Conventional Technologies
3.11 Polymerase Chain Reaction (Pcr) Technology
Chapter 4 Cancer Diagnostics Market
4.1 Forces Driving Growth
4.2 Cancer Markets
4.3 Market for Next-Generation Cancer Diagnostics by Cancer Site
4.4 Market for Next-Generation Cancer Diagnostics by Purpose of Analysis
4.5 Market for Next-Generation Cancer Diagnostics by Test Platform
4.6 Market for Test Platforms by Cancer Site
4.7 Market by Diagnostic Segment
Chapter 5 Market Breakdown Application by Cancer Site
Chapter 7 Evaluation of the Market Based on Geographic Region
Chapter 8 Patents
Chapter 9 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/qyxnpu
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.